Autoimmune Hepatitis: When Your Immune System Attacks Your Liver

Autoimmune hepatitis (AIH) is a chronic liver disease in which your own immune system — the system designed to protect you — mistakes your liver cells for foreign invaders and attacks them. Unlike viral hepatitis (caused by a virus), alcohol-related liver disease (caused by alcohol), or NAFLD (caused by metabolic factors), autoimmune hepatitis has no external cause you can point to or remove. Your body is doing this to itself.

That fundamental reality shapes everything about AIH — the treatment (suppressing your own immune system), the duration (lifelong in most cases), the emotional experience (a disease that feels random and uncontrollable), and the prognosis (excellent with treatment, potentially fatal without it). If you've just been diagnosed, or if you've been living with AIH and want to understand it more deeply, this guide covers the full picture.

What's happening inside your liver

In autoimmune hepatitis, your immune system's T-cells and autoantibodies target proteins on the surface of your hepatocytes (liver cells). The attack triggers a chronic inflammatory response — immune cells infiltrate the liver tissue, damaged hepatocytes die and are replaced, and if the inflammation isn't controlled, scar tissue (fibrosis) accumulates progressively.

Left untreated, AIH follows the familiar liver disease trajectory: chronic inflammation → progressive fibrosis → cirrhosis → decompensation → liver failure. The timeline varies — some patients progress rapidly (months), others slowly (decades) — but the direction without treatment is consistent. The critical difference between AIH and most other liver diseases: treatment with immunosuppressive medication can halt and often reverse the damage — even in patients who present with significant fibrosis.

Who gets autoimmune hepatitis

AIH can affect anyone at any age, but it has a strong demographic pattern. It's approximately 3–4 times more common in women than men. It has a bimodal age distribution — one peak in adolescence/young adulthood (ages 10–30) and another in middle age (ages 40–60). It's more common in people with other autoimmune conditions — thyroid disease (Hashimoto's, Graves'), celiac disease, type 1 diabetes, rheumatoid arthritis, ulcerative colitis, and others. If you have one autoimmune condition, you're more likely to develop another — and AIH can be part of that pattern. There's a genetic predisposition — certain HLA (human leukocyte antigen) types are associated with higher AIH risk. Family history of autoimmune disease increases your risk, even if nobody in your family has had liver disease specifically.

The cause is unknown. Researchers believe AIH develops when a genetically susceptible person encounters an environmental trigger (a virus, a medication, a toxin) that activates the immune system against liver cells. But the specific trigger is rarely identified — which is frustrating for patients who want to know "why me?"

Types of autoimmune hepatitis

The type is determined by which autoantibodies are present in your blood — tested during the diagnostic workup. Both types are treated with the same medications (immunosuppression), though Type 2 may require higher doses or additional agents.

How autoimmune hepatitis is diagnosed

AIH diagnosis involves combining several lines of evidence — there's no single definitive test. The diagnostic workup typically includes:

Blood tests: Elevated ALT and AST (often significantly — 5–20x normal in acute presentations). Elevated IgG (immunoglobulin G) — a hallmark of AIH. Autoantibodies — ANA, SMA, anti-LKM1, and others. Normal or mildly elevated ALP and GGT (distinguishing AIH from cholestatic diseases like PBC and PSC). Use the Liver Enzyme Checker to understand your results.

Liver biopsy: Often essential for confirming the diagnosis. The pathologist looks for a characteristic pattern: "interface hepatitis" (inflammation at the border between portal tracts and liver lobules), plasma cell infiltration (plasma cells are the hallmark immune cells of AIH), hepatocyte rosette formation, and the degree of fibrosis. Biopsy also rules out other causes that can mimic AIH.

Exclusion of other causes: Viral hepatitis (B and C) must be ruled out. Drug-induced liver injury (DILI) can mimic AIH. Wilson's disease must be excluded (particularly in younger patients). Alcohol use must be assessed. This is important because the treatment for AIH (immunosuppression) would be harmful if the real diagnosis is viral hepatitis or Wilson's disease.

Simplified diagnostic score: The International Autoimmune Hepatitis Group developed a scoring system that combines autoantibody levels, IgG levels, biopsy findings, and exclusion of viral hepatitis into a probability score (probable vs definite AIH). Most hepatologists use this system.

Treatment: suppressing the fire

The treatment for AIH is immunosuppression — calming your immune system enough to stop it from attacking your liver while preserving enough immune function to fight infections and cancers. The standard approach has been used for decades and works remarkably well:

Induction (getting the fire under control)

Prednisone (or prednisolone): Started at 0.5–1 mg/kg/day (typically 30–60 mg daily) and tapered gradually over several weeks as liver enzymes improve. Steroids provide rapid, powerful immunosuppression that brings the acute inflammation under control.

Azathioprine (Imuran): Added either at the start or after 2 weeks. Azathioprine is the steroid-sparing agent — it allows the steroid dose to be reduced while maintaining immunosuppression. Typical maintenance dose: 1–2 mg/kg/day (50–150 mg daily). Before starting azathioprine, your doctor should test for TPMT (thiopurine methyltransferase) enzyme activity — a small percentage of patients have genetic variants that make azathioprine dangerously toxic at standard doses.

The goal of induction: normalize ALT, AST, and IgG within 6–12 months. Most patients respond well — 65–80% achieve biochemical remission (normal labs) with standard therapy.

Maintenance (keeping the fire out)

Once remission is achieved, prednisone is tapered to the lowest effective dose (ideally off entirely) while azathioprine continues as the maintenance agent. Many patients are maintained on azathioprine alone (50–150 mg daily) for years — sometimes indefinitely.

Can you stop treatment? This is one of the most discussed questions in AIH. Some patients can be successfully withdrawn from immunosuppression after sustained remission (typically 2+ years of completely normal labs and a biopsy showing no active inflammation). However, relapse after stopping treatment occurs in approximately 50–80% of patients — most within the first year of withdrawal. Because of this high relapse rate, many hepatologists recommend indefinite maintenance therapy rather than attempting withdrawal. If withdrawal is attempted, it must be done very gradually under close monitoring.

When standard therapy doesn't work

Approximately 10–15% of patients don't respond adequately to prednisone + azathioprine, or can't tolerate azathioprine's side effects (nausea, liver toxicity, low white blood cells). Alternative options include mycophenolate mofetil (CellCept) as an azathioprine substitute, tacrolimus or cyclosporine for refractory cases, budesonide (a steroid with less systemic side effects, useful in non-cirrhotic patients), rituximab (for severe refractory cases), and infliximab (anti-TNF therapy, in select situations).

Living with autoimmune hepatitis: the daily reality

Medication side effects

The side effects of immunosuppressive medication are often the hardest part of living with AIH: prednisone side effects (especially at higher doses) include weight gain, moon face, acne, mood swings, insomnia, elevated blood sugar, bone density loss, and increased infection susceptibility. These improve substantially as the dose is tapered. Azathioprine side effects include nausea, fatigue, low white blood cell count (requiring periodic blood monitoring), and rare but serious liver toxicity. The side effects are real and can significantly impact quality of life — but the alternative (untreated AIH progressing to cirrhosis) is worse.

Monitoring

Regular blood work is essential — typically every 1–3 months during active treatment, every 3–6 months during stable remission. Tests include ALT, AST, IgG (should be normal in remission), CBC (monitoring for azathioprine-related blood count suppression), metabolic panel (monitoring blood sugar, kidney function), and liver synthetic function (albumin, INR, bilirubin). Upload every lab report to LiverTracker. Your trend charts tell the story of whether your disease is controlled, improving, or relapsing. A rising ALT or IgG after a period of normalization is an early relapse signal — often visible on the trend chart before symptoms appear. Share with your hepatologist before every appointment.

Flares and relapses

AIH can flare — periods where the immune attack intensifies, ALT and AST spike, and symptoms (fatigue, jaundice, nausea) return. Flares can be triggered by medication reduction or withdrawal, non-compliance with immunosuppression, pregnancy (immune changes can trigger flares postpartum), infections, or sometimes without any identifiable trigger. Flares are treated by increasing immunosuppression — typically resuming or increasing the steroid dose and ensuring azathioprine is at an adequate level. Prompt recognition (through regular lab monitoring and symptom awareness) allows flares to be caught and treated before significant liver damage occurs.

Bone health

Long-term steroid use (even at low maintenance doses) accelerates bone loss. All AIH patients on chronic prednisone should take calcium (1,000–1,200 mg/day) and vitamin D (1,000–4,000 IU/day) supplementation, get baseline and periodic DEXA scans to monitor bone density, engage in weight-bearing exercise, and discuss bisphosphonate therapy if bone density declines significantly.

Prognosis: the encouraging news

With treatment, the prognosis for autoimmune hepatitis is genuinely good: 10-year survival with treatment is approximately 80–90%. Many patients achieve sustained remission and live normal lifespans. Even patients who present with significant fibrosis can experience fibrosis regression with effective immunosuppression — the liver can heal when the immune attack is controlled. Patients who present before cirrhosis develops have the best outcomes.

Without treatment, the prognosis is very different: untreated AIH has a 50% 5-year mortality rate. The contrast between treated and untreated outcomes makes AIH one of the most treatment-responsive liver diseases — and one where early diagnosis and adherence to therapy matter enormously.

For patients who do progress to cirrhosis despite treatment (or who present with established cirrhosis), management follows the standard cirrhosis care pathway — HCC screening, variceal screening, ascites management, and transplant evaluation when indicated. AIH can recur after transplant (in about 20–30% of cases), but recurrence is usually mild and manageable with continued immunosuppression.

Frequently asked questions

Did I do something to cause autoimmune hepatitis?

No. AIH is not caused by anything you did, ate, drank, or were exposed to. It's an autoimmune condition — your immune system misfires due to a combination of genetic predisposition and unknown environmental triggers. Like type 1 diabetes, rheumatoid arthritis, or lupus, it's not a lifestyle disease. You didn't cause it and you couldn't have prevented it.

Will I need to take medication forever?

Possibly. Many patients require indefinite low-dose immunosuppression (azathioprine maintenance) because the relapse rate after stopping treatment is 50–80%. Some patients can be successfully withdrawn after 2+ years of complete remission — but this must be done gradually under close monitoring, and many who attempt withdrawal eventually relapse and need to restart. Think of it as managing a chronic condition (like blood pressure medication) rather than curing an acute illness.

Can autoimmune hepatitis be cured?

Controlled — yes, in most patients. Cured — not definitively. Treatment suppresses the immune attack and allows the liver to heal, and some patients achieve long-term remission off medication. But the underlying immune predisposition remains, and relapse is always possible. "Managed into sustained remission" is a more accurate description than "cured" for most patients.

Is autoimmune hepatitis the same as autoimmune liver disease?

"Autoimmune liver disease" is a broader category that includes AIH, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). All three involve immune-mediated liver damage, but they affect different parts of the liver (AIH targets hepatocytes; PBC and PSC target bile ducts) and have different treatments. Some patients have "overlap syndromes" — features of more than one autoimmune liver disease simultaneously — which require combined treatment approaches.

Can I get pregnant with autoimmune hepatitis?

Yes — many women with AIH have successful pregnancies. However, pregnancy requires careful management: azathioprine is generally continued during pregnancy (classified as compatible with pregnancy by most guidelines, despite its FDA category). Prednisone is safe during pregnancy. Mycophenolate must be stopped before conception (teratogenic — causes birth defects). Flares can occur during pregnancy (particularly in the third trimester and postpartum), so monitoring must be intensified. Plan pregnancy in collaboration with your hepatologist and obstetrician.

Does autoimmune hepatitis increase my cancer risk?

AIH patients with cirrhosis have an increased risk of hepatocellular carcinoma (HCC) — similar to cirrhosis from any cause. HCC screening (AFP + ultrasound every 6 months) is recommended for all AIH patients with cirrhosis. AIH patients without cirrhosis don't require HCC screening. Long-term immunosuppression slightly increases the risk of certain other cancers (lymphoma, skin cancer) — regular cancer screening and sun protection are important.

Autoimmune hepatitis isn't something you caused, and it isn't something you can fight with willpower. It's a medical condition that responds beautifully to medical treatment. Take the medication. Monitor your labs. And know that with treatment, most AIH patients live long, full lives.

→ Check Your Liver Enzymes Free

→ Start Tracking Free

→ Calculate Your MELD Score

Medical Disclaimer: This article is for informational and educational purposes only. Autoimmune hepatitis management should be directed by a hepatologist experienced in autoimmune liver disease. Never change immunosuppressive medication doses without medical guidance. Visit livertracker.com/medical-disclaimer.